Immunex Enbrel Sales Capped At $800 Mil. With Current Production Capacity
Executive Summary
Sales of Immunex' rheumatoid arthritis drug Enbrel (etanercept) in the U.S. are capped at $800 mil. a year at the current manufacturing capacity, Immunex said in an Aug. 9 Securities & Exchange Commission filing.
You may also be interested in...
Biopharma Protein Shortages Will Be Addressed By Supplier Alliances - Lilly
Biopharmaceutical manufacturing alliances will be on the rise over the next two to three years as companies address the expected shortfall in protein supply, Lilly Fermentation and Cell Culture Process Development Head Morris Rosenberg predicted.
Biopharma Protein Shortages Will Be Addressed By Supplier Alliances - Lilly
Biopharmaceutical manufacturing alliances will be on the rise over the next two to three years as companies address the expected shortfall in protein supply, Lilly Fermentation and Cell Culture Process Development Head Morris Rosenberg predicted.
Enbrel Sales Near Production Cap; New Plant To Produce Clinical Lots In 2001
Immunex will use its newly acquired Rhode Island production facility to supply Enbrel (etanercept) for clinical trials during 2001.